LFWD Lifeward Ltd.

Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies L3 CIK: 0001607962
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Despite exceptional 1473.9% YoY revenue growth, Lifeward is in severe financial distress with unsustainable cash burn of $16.8M annually against only $2.2M in cash reserves, creating an imminent solvency crisis. Operating expenses of ~$28M far exceed the $8.4M gross profit, indicating fundamental business model dysfunction where revenue growth is not translating to viable unit economics or profitability.

Strengths

  • + Exceptional revenue growth of 1473.9% YoY indicates strong market demand for orthopedic/prosthetic products
  • + Reasonable gross margin of 38.2% suggests acceptable pricing power in the medical device sector
  • + Low long-term debt of $394K provides minimal leverage burden

Risks

  • ! Critical liquidity crisis: $16.8M annual operating cash burn with only $2.2M cash reserves equals <2 months runway before insolvency
  • ! Operating margin of -89.3% and deteriorating net losses despite revenue growth indicate fundamental cost structure misalignment with revenue base
  • ! Quick ratio of 0.84 signals immediate working capital stress; company will require external funding or face bankruptcy within months
  • ! Operating expenses (~$28M) massively exceed gross profit ($8.4M), suggesting company loses money on operations despite revenue
  • ! No clear path to profitability evident in trajectory; revenue growth obscures deteriorating underlying economics

Key Metrics to Watch

Financial Metrics

Revenue
22.0M
Net Income
-19.9M
EPS (Diluted)
$-17.16
Free Cash Flow
-16.8M
Total Assets
22.9M
Cash
2.2M

Profitability Ratios

Gross Margin 38.2%
Operating Margin -89.3%
Net Margin -90.4%
ROE -236.8%
ROA -87.0%
FCF Margin -76.4%

Balance Sheet & Liquidity

Current Ratio
1.31x
Quick Ratio
0.84x
Debt/Equity
0.05x
Debt/Assets
63.3%
Interest Coverage
N/A
Long-term Debt
394.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-12T13:18:23.287648 | Data as of: 2025-12-31 | Powered by Claude AI